The QualityStocks Daily Monday, July 25th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(GOVX) $1.5900 +150.39%

MarketClub Analysis(KOSS) $11.2000 +42.68%

MarketBeat(BIVI) $2.4600 +11.31%

The QualityStocks Daily Stock List

Tonix Pharmaceuticals Holding (TNXP)

StockMarketWatch, QualityStocks, BUYINS.NET, MarketBeat, TraderPower, InvestorPlace, PennyStockLocks, StockRockandRoll, MarketClub Analysis, StreetInsider, Penny Stock 101, The Online Investor, Barchart, Marketbeat.com, RedChip, INO.com Market Report, HotOTC, Daily Trade Alert, Buzz Stocks, OTCtipReporter, Penny Pick Finders, StockOnion, Trades Of The Day, TopPennyStockMovers, Streetwise Reports, Street Insider, PennyStockProphet, Profitable Trader Authority, MarketWatch, Schaeffer's, Small Cap Firm, Promotion Stock Secrets, Penny Stock 109, Investment House, Investing Futures, plrinvest, The Street, FeedBlitz, Penny Stock 103, Weekly Wizards, Wealth Insider Alert and Jason Bond reported earlier on Tonix Pharmaceuticals Holding (TNXP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) (FRA: TPMR) is a biopharmaceutical firm that focuses on the discovery, acquisition, development, manufacture and licensing of biologics and small molecules to prevent and treat various ailments like post-traumatic stress disorder and fibromyalgia syndrome.

Tonix Pharmaceuticals has its headquarters in Chatham, New Jersey and was founded on November 16, 2007 by Donald W. Landry and Seth Lederman.

Tonix Pharmaceuticals’ immunology product candidates include CNS (central nervous system) product candidates that are made up of biologics and small molecules for treating addiction, psychiatric, neurologic and pain conditions, as well as biologics that address autoimmune, cancer and immunosuppression ailments, as well as vaccines that prevent infectious diseases.

Tonix Pharmaceuticals’ lead product candidate is a live replicating vaccine developed to protect against the coronavirus called TNX-1800. The firm’s vaccines also include TNX-2600 and TNX-2300, which are also live replicating vaccine candidates developed to prevent the coronavirus and a live horsepox virus vaccine indicated for smallpox prevention dubbed TNX-801. Additionally, the firm’s central nervous system product candidate is a cyclobenzaprine formulation; TNX-102 SL, which is currently in phase 2 studies for alcohol use disorder and Alzheimer’s disease agitation as well as in phase 3 development for fibromyalgia. Other products in the firm’s preclinical pipelines include the TNX-1700, which is indicated for pancreatic and gastric cancers, TNX-1200; developed as a vaccine for smallpox and TNX-1600, which has been indicated for PTSD.

Tonix Pharmaceuticals recently licensed technology which will be used to treat Prader-Willi syndrome, which has no approved treatments available in the market. This effort could allow the firm to expand their intranasal potentiated oxytocin development program to a new indication, which would be beneficial both for the firm’s growth and its shares.

Tonix Pharmaceuticals Holding (TNXP), closed Monday's trading session at $1.73, up 45.3782%, on 53,741,856 volume. The average volume for the last 3 months is 53.742M and the stock's 52-week low/high is $1.19/$26.08.

GeoVax Labs (GOVX)

Wall Street Resources, IRGnews Alert, Standout Stocks, QualityStocks, MarketClub Analysis, MarketBeat, Penny Performers, BUYINS.NET, InvestorPlace, SmallCapStockPlays, SmallCapVoice, Stock News Now, Stock Stars, Stockpalooza, PoliticsAndMyPortfolio, HotOTC, DrStockPick, Daily Market Beat, CoolPennyStocks, FeedBlitz, M2 Communications, PennyTrader.com, ProActive Capital, Schaeffer's, The Street, TradersPro, Wall Street Mover and PennyOmega reported earlier on GeoVax Labs (GOVX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GeoVax Labs Inc. (NASDAQ: GOVX) (FRA: E8L) is a clinical stage biotechnology firm which is engaged in the development, manufacture, testing, licensing and commercialization of human vaccines that prevent and fight ailments caused by HIV-1 and other infectious agents.

The firm operates as part of the biotechnology research services industry and has its headquarters in Smyrna, Georgia. The company was founded in 1988 by Donald G. Hildebrand and Harriet Latham Robinson.

This firm is party to partnership and collaboration agreements with Leidos Inc., the University of California, the Geneva Foundation, Viamune Inc., American Gene Technologies International Inc., the Burnet Institute, the Scripps Research Institute, the University of Maryland Institute of Human Virology, University of Texas Medical Branch, Georgia State University Research Foundation, University of Pittsburgh, Emory University, U.S. Naval Research Laboratory, U.S. Army Research Institute of Infectious Disease, U.S. Department of Defense, the CDC, the HIV Vaccines Trial Network and the National Institute of Allergy and Infectious Diseases of the NIH.

The company is currently developing preventive vaccines against malaria, Zika virus, HIV and the coronavirus as well as hemorrhagic fever viruses like Lassa, Marburg and Ebola; and therapeutic vaccines for chronic Hepatitis B infections and HIV. Additionally, the firm is developing immunotherapies for solid tumor cancers.

This biotechnology firm is at the forefront of forward-thinking vaccine science. Its clinical success has improved its financial position as well its capital structure, which allows it secure long-term funding. Many expect the company to reach numerous vaccine development milestones over the next year, which will benefit both the firm and its shareholders.

GeoVax Labs (GOVX), closed Monday's trading session at $1.59, up 150.3937%, on 213,285,627 volume. The average volume for the last 3 months is 203.027M and the stock's 52-week low/high is $0.5495/$7.50.

FONU2 Inc. (FONU)

PennyStocks24, QualityStocks, OTC Stock Review, SmallCapVoice, DSR News, TheNextBigTrade, BestDamnPennyStocks, PHUB News, PennyStock MarketBulls, Penny Stock Newsletter, Penny Stock Hub, Penny Picks, JackpotStock Picks, OTCJournal, Blaque Capital Stocks, PennyStockRumors.net, Email Stock Picks, Damn Good Penny Picks, Otcstockexchange, PennyStock PayCheck, Actual Gains, PennyStockLocks.com, Xtreme Stock Picks, PREPUMP STOCKS, PricelessPennyStocks, RagingStock Bull, ResearchOTC, SmallCap Network, SmallCapNetwork, Stock Exploder, StockRockandRoll, Whisper from Wall Street and PennyStockInformer reported earlier on FONU2 Inc. (FONU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FONU2 Inc. (OTC: FONU) is a social commerce services firm that provides a precision mobile sales and marketing platform which functions like a booking and order reservation system.

The firm has its headquarters in Rincon, Georgia and was incorporated in 2011, on October 25th by Jeffrey M. Pollitt. Prior to its name change in April 2002, the firm was known as Cygnus Internet Inc. It serves consumers in the United States.

The enterprise develops a value-added debit card and also develops mobile apps that bring buyers’ and sellers’ products and services. These products can be found on eBay as well as on its website. It is focused on completing the development of mobile services that will allow the establishment of its platform as a go-to destination for users to search and list products, make payments and schedule appointments in real time. The enterprise also operates as a film studio and production firm. It is focused on developing a film studio complex. Its Moon River Rentals LLC subsidiary also purchases equipment used for commercial, television and film production. The enterprise holds distribution rights to Yellow, a Nick Cassavetes’ film. It has also established a film division to produce motion pictures, as well as construct and operate a movie studio. Its target market is international and domestic film distributors and theater patrons.

The company is focused on building shareholder confidence and value as it realizes its goal to become a national company. This will be good for investments into the company as well as its growth.

FONU2 Inc. (FONU), closed Monday's trading session at $0.0002, up 48.1481%, on 2,341,986,638 volume. The average volume for the last 3 months is 2.342B and the stock's 52-week low/high is $0.000001/$0.0028.

Redbox Entertainment (RDBX)

QualityStocks, Schaeffer's, MarketClub Analysis, Trades Of The Day, MarketBeat and Daily Trade Alert reported earlier on Redbox Entertainment (RDBX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Redbox Entertainment Inc. (NASDAQ: RDBX) is an entertainment firm which affords consumers access to various content across physical and digital media.

The firm has its headquarters in Oakbrook Terrace, Illinois and was incorporated in 2002. Prior to its name change, the firm was known as Seaport Global Acquisition Corp. The firm has 810 companies in its corporate family and serves consumers in the United States.

The company specializes in Blu-ray, DVD and video game rentals through automated retail kiosks. Its kiosks are located at pharmacies, mass retailers, grocery stores, fast food restaurants, and convenience stores, and usually have its signature red color.

The enterprise operates a digital streaming service which offers channels of FAST (free advertisement supported streaming television), as well as both paid movies from Hollywood content partners and studios and AVOD (advertising-based video on demand). Its Redbox application is available on various entertainment platforms, including connected TVs, Roku devices, the Web and gaming platforms, as well as Android and iOS devices. Its application also operates kiosks across the U.S. at thousands of retail locations, which gives consumers access to the entertainment. In addition to this, the enterprise also acquires,produces and distributes movies via its Redbox Entertainment label, providing rights to films which are distributed through 3rd party digital services as well as across its physical and digital services.

The firm recently entered into a distribution agreement with LG Electronics which will allow Redbox Free Movies to be viewed on LG Channels. These FAST channels will afford LG Channel viewers an extensive range of great TV programs and movies, which will boost interaction with Redbox’s products. This will, in turn, positively impact the firm’s revenues.

Redbox Entertainment (RDBX), closed Monday's trading session at $5.55, up 81.9672%, on 108,602,283 volume. The average volume for the last 3 months is 108.602M and the stock's 52-week low/high is $1.6101/$27.22.

Propanc Biopharma (PPCB)

QualityStocks, MarketBeat, Wall Street Mover and PoliticsAndMyPortfolio reported earlier on Propanc Biopharma (PPCB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Propanc Biopharma Inc. (OTCQB: PPCB) is a clinical stage biopharmaceutical firm that is engaged in developing cancer treatments for colorectal, ovarian and pancreatic cancer.

The firm has its headquarters in Camberwell, Australia and was incorporated in 2007, on October 15th by Julian Kenyon and James Nathanielsz. Prior to its name change in April 2017, the firm was known as Propanc Health Group Corp. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in Australia.

The company is party to a research collaboration agreement with the University of Jaén, which entails the commencement of a joint drug discovery program, POP1. Its long-term therapies are based on pancreatic proenzyme formulations which suppress metastasis and tumor recurrence.

The enterprise’s product pipeline comprises of a formulation dubbed PRP, which is in its pre-clinical phase of development and has been developed to improve the anti-cancer effects of multiple enzymes which act synergistically. This formulation is made up of 2 pancreatic proenzymes, i.e. chymotrypsinogen and trypsinogen, for the treatment of cancer. Its approach prevents the metastasis and recurrence of solid tumors through the use of these proenzymes that target and eliminate cancer stem cells in patients with colorectal, ovarian or pancreatic cancer.

The firm’s PRP cancer stem cell technology may be key in helping find a cure for cancer, as stem cell therapeutics continue evolving for the prevention and treatment of metastatic cancer. The technology’s use in controlling malignant tumor spread may not only meet the needs of patients with these indications but also bring in significant revenue into the firm, as well as attract additional investors.

Propanc Biopharma (PPCB), closed Monday's trading session at $0.0047, up 38.2353%, on 105,467,790 volume. The average volume for the last 3 months is 104.348M and the stock's 52-week low/high is $0.0018/$0.052.

ReneSola Ltd (SOL)

The Street, StocksEarning, MarketBeat, Zacks, Money Morning, SmarTrend Newsletters, China Vesting, Streetwise Reports, Trade of the Week, StreetInsider, Alternative Energy, Investor Ideas, Marketbeat.com, InvestorPlace, QualityStocks, Top Stock Picks, Daily Markets, TradersPro, Taipan Daily, ProfitableTrading, StreetAuthority Daily, Energy and Capital, Trading Concepts, MarketClub Analysis, InvestorIntel, PoliticsAndMyPortfolio, Hit and Run Candle Sticks, AllPennyStocks, Inside Investing Daily, TopStockAnalysts, Schaeffer's, PennyOmega, DrStockPick, Daily Trade Alert, TopPennyStockMovers, CRWEWallStreet, PennyToBuck, CRWEFinance, Green Chip Review, Cabot Wealth, BUYINS.NET, BestOtc, AnotherWinningTrade, Trades Of The Day, CRWEPicks, FeedBlitz, Green Chip Stocks, The Best Newsletters, Street Insider, StockMarketWatch, Stockhouse, StockHotTips, Jason Bond, Market FN, Stock Research Newsletter, Stock Analyzer, smartOTC, SmallCapInvestor.com and The Online Investor reported earlier on ReneSola Ltd (SOL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ReneSola Ltd (NYSE: SOL) (FRA: VQKB) (BMV: SOLN) is a solar project developer and operator that is focused on the development, building, operation and sale of solar power projects.

The firm has its headquarters in Stamford, Connecticut and was incorporated in 2005. It operates as part of the solar industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in Canada, Europe and the United States.

The company’s strategy is to pursue project development opportunities. It operates through the Electricity Generation revenue, EPC Services (Engineering, procurement and Construction) and Solar Power Project Development segments. It generates most of its revenue from the Project development segment. The company operates through the Hungary, Poland, France, Turkey, England, Romania, Canada, United States and China geographical categorizations.

The enterprise is involved in the generation and sale of electricity as well as the development of community solar gardens. It also sells project rights while its EPC business offers balance-of-system components, procurement of solar modules and construction contracting and management services as well as engineering design. As of December 2021, the enterprise operated roughly 100 solar power projects with an estimated capacity of 180 megawatts.

The firm was recently awarded 20-year Index REC (Renewable energy contracts) for 2 solar projects as part of New York’s goal to increase the use of renewable energy. This move, which is favorable to the environment and its inhabitants, not only opens the firm up to new growth opportunities but will also bring in additional revenues and investments.

ReneSola Ltd (SOL), closed Monday's trading session at $4.91, even for the day, on 406,200 volume. The average volume for the last 3 months is 402,798 and the stock's 52-week low/high is $3.46/$9.72.

Kuke Music (KUKE)

InvestorPlace reported earlier on Kuke Music (KUKE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kuke Music Holding Ltd (NYSE: KUKE) is an investment holding firm that is engaged in the provision of classical music licensing, education and subscription services.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in 2017, on September 13th by Yu He. It operates as part of the entertainment industry, under the communication services sector. The firm serves consumers in China.

The company operates through its subsidiaries, which are involved in the commercial distribution and operation of video and music content as well as the sale of music education solutions.

The enterprise operates through the Smart music education solutions and Non-pop music subscription and copyright licensing segments. The music education solutions segment comprises of integrated kukey smart pianos and self-developed smart teaching systems which have been designed to allow one-to-many teaching in an interactive synchronous learning environment. This serves all levels of educational institutions, from kindergartens to colleges and universities. On the other hand, the licensing segment licenses its music content to digital music service providers and online music entertainment platforms. It operates through its mobile application and websites. Its clients include public libraries, colleges and universities in China. Its copyright licensing clients also include game developers and smart hardware manufacturers.

The firm recently announced its latest financial results, which show significant increases in its revenues and profits. It remains focused on providing its smart music learning solutions to public schools, which will bring in additional revenues into the firm while helping create value for its shareholders.

Kuke Music (KUKE), closed Monday's trading session at $1.4801, up 4.9716%, on 9,011 volume. The average volume for the last 3 months is 8,836 and the stock's 52-week low/high is $1.175/$7.15.

Expion360 Inc. (XPON)

We reported earlier on Expion360 Inc. (XPON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Expion360 Inc. (NASDAQ: XPON) is focused on designing, assembling, manufacturing and selling lithium iron phosphate batteries and supporting accessories.

The firm has its headquarters in Redmond, Oregon and was incorporated in 2016, on June 16th by John Yozamp. Prior to its name change in November 2021, the firm was known as Yozamp Products Company LLC. It operates as part of the electrical equipment and parts industry, under the industrials sector. The firm serves consumers across the globe, with its primary focus being the United States.

The company’s objective is to enable consumers to power anything, anywhere without any hitch. Its batteries are based on LiFePO4 (lithium iron phosphate), which is considered to be the ideal choice for high energy density, longevity, dependability and safety.

The enterprise’s product offerings include minimal and dense-footprint batteries in the marine and recreational vehicle industry. It also develops the e360 Home Energy Storage systems. This is in addition to being involved in the provision of a range of industrial tiedown models, bus bars, terminal blocks, and battery monitors. Its batteries are provided under the VPR 4EVER brand name for off-the-grid, residential, industrial, gold, marine and recreational vehicle applications. The enterprise serves original equipment manufacturers, wholesalers and dealers.

The firm, which recently launched its new Expion360 Lithium Power Bundle product, is planning to construct a large-scale factory project for Li-ion batteries. This move will not only eliminate constraints that the firm faces in its supply chains but also extend its consumer reach.

Expion360 Inc. (XPON), closed Monday's trading session at $3.05, even for the day, on 107,897 volume. The average volume for the last 3 months is 107,697 and the stock's 52-week low/high is $2.09/$11.29.

374Water Inc. (SCWO)

We reported earlier on 374Water Inc. (SCWO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

374Water Inc. (NASDAQ: SCWO) is a cleantech firm that is engaged in the provision of a technology which addresses environmental pollution challenges.

The firm has its headquarters in Durham, North Carolina and was incorporated in 2021, on April 30th by Marc Deshusses and Yaacov Nagar. It operates as part of the pollution and treatment controls industry, under the industrials sector. The firm serves consumers around the world.

The company has developed an innovative technology which enables a circular economy and the creation of a world without waste. Its mission is to preserve a healthy and clean environment which sustains life. The company applies cutting-edge engineering and science to recover resources from waste, to keep water for drinking clean.

The enterprise’s waste treatment system, dubbed the AirSCWO system, is based on supercritical water oxidation technology. They are used in the treatment of a range of non-hazardous and hazardous waste streams to eliminate emerging contaminants, pharmaceuticals, microplastics and dioxane. Its clients include channel partners like technology integrators, engineering-procurement and construction firms, operations service providers, waste service providers and NGOs; and end-users, which include agricultural companies, food waste, army camps, chemical plants, environmental remediation and waste management firms, industrial manufacturing facilities, utilities and governmental entities.

The company recently appointed a new VP of sales who has decades of experience in water and waste management. This addition will help accelerate the company’s growth in the market and may positively influence investments into the company, which will help create shareholder value.

374Water Inc. (SCWO), closed Monday's trading session at $1.875, up 0.26738%, on 22,362 volume. The average volume for the last 3 months is 22,362 and the stock's 52-week low/high is $1.00/$6.68.

Ribbon Communications (RBBN)

StockMarketWatch, MarketBeat, InvestorPlace, Zacks, Wealth Insider Alert and Daily Trade Alert reported earlier on Ribbon Communications (RBBN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ribbon Communications Inc. (NASDAQ: RBBN) (FRA: NU42) is engaged in the provision of communications technology.

The firm has its headquarters in Plano, Texas and was incorporated in 1997. Prior to its name change in November 2017, the firm was known as Sonus Networks Inc. It operates as part of the telecom services industry, under the communication services sector. The firm serves consumers around the globe, with a focus on consumers in the Asia Pacific, Africa, the Middle East, Europe and the United States.

The enterprise operates through the IP Optical Networks and the Cloud and Edge segments. The IP Networks segment is involved in providing software and hardware solutions for IP networking, routing, switching and optical transport to enable and support technologies like 5G and corresponding applications. It also provides multiple solutions, including legacy NTR, data center interconnection, core networking, metro and edge aggregation, 5G-native solutions for mobile-backhaul and transport solutions for wholesale carriers. This segment serves service providers as well as education, research, transportation, finance, defense, government and utilities industries. On the other hand, the Cloud segment is engaged in the provision of hardware and software products, and services and solutions for enabling voice over 5G communications, voice over long-term evolution, voice over internet protocol communications, and unified communications and collaboration. It also provides network transformation and session border controller products. This segment serves hybrid, public or private cloud infrastructures, as well as service provider networks, enterprise premises and data centers.

The company recently entered into a partnership with DSTNY Automate, which will allow telecom operators to accelerate their ability to deliver services to consumers. In addition to helping extend the company’s reach, this move will bring in additional revenue and help generate value for the company’s shareholders.

Ribbon Communications (RBBN), closed Monday's trading session at $3.58, up 9.1463%, on 606,109 volume. The average volume for the last 3 months is 606,109 and the stock's 52-week low/high is $2.57/$7.78.

Marathon Digital Holdings Inc. (MARA)

InvestorPlace, MarketClub Analysis, Schaeffer's, StockMarketWatch, QualityStocks, MarketBeat, TradersPro, Lebed.biz, BUYINS.NET, StocksEarning, The Online Investor, Trades Of The Day, The Street, Daily Trade Alert, TraderPower, Marketbeat.com, PoliticsAndMyPortfolio, TopPennyStockMovers, Wall Street Mover, FeedBlitz, Kiplinger Today, Wealth Insider Alert, StreetAuthority Daily, InvestorsUnderground, Barchart, DreamTeamNetwork, RedChip, AllPennyStocks, Stock Analyzer, Stock Beast, StockOodles, Street Insider, StreetInsider and Promotion Stock Secrets reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Distributed ledger or blockchain technology is the infrastructure that granted cryptocurrencies increased security, instant traceability, and enhanced speed and efficiency. Even as the crypto market experiences unprecedented drops in prices, blockchain technology is still in high demand because of its security and efficiency benefits. The latest skill index reveals that many American companies are hungry for skilled blockchain technicians, making blockchain tech jobs some of the most in-demand occupations in the country.

Businesses are paying top dollar for blockchain experts who can help them integrate blockchain into their systems and significantly beef up their security. The following are five in-demand blockchain tech jobs.

Risk analyst. Usually employed by government enterprises or financial companies, risk analysts are typically tasked with ensuring their employer’s actions are in line with local and governmental ordinances. They are responsible for handling the technical side of a business’s risk management, compiling and analyzing data before forwarding it to managers who formulate possible solutions.

This position calls for plenty of research experience, expert-level proficiency with Excel and an intuitive business sense.

Analyst relation manager. As an analyst relations manager, you will be the link between industry analysts and the marketing team. It is a crucial role that is integral to establishing brand image, raising awareness of a company’s product in the marketplace, and increasing knowledge sharing and awareness between a company and its target audience.

To qualify as an analyst relation manager, you will require a technology or marketing degree, a background in marketing or corporate communications, some managerial experience with an agency, hands-on AR experience, and at least three to five years of experience working with a technology vendor.

Technical architect. Technical architects tend to have top-notch technical and managerial skills. Also referred to as IT systems architects, this role involves creating, maintaining and implementing technology systems. You will be charged with designing IT systems, managing their implementation and liaising with the software development team to ensure the system is working effectively.

You will require a software engineering degree and a PGDM or MBA to qualify as a technical architect.

Crypto community manager. As a crypto community manager, you will be tasked with tracking and presenting the engagement of all relevant business statistics. This role is crucial to marketing and client interactions, and it calls for a complete understanding of project fundamentals. It doesn’t usually have rigid educational requirements, and many organizations are willing to hire newbies who can learn and grow with the company.

Blockchain legal consultant. This consultant will be responsible for forming legal partnerships and issuing legal advice on how to structure cryptocurrency offerings. They will provide expert counsel to clients on how to develop blockchain-based solutions, create or use cryptocurrencies, and integrate blockchain-based technologies into their systems based on blockchain regulations and laws.

To qualify as a blockchain legal consultant, you will need a certified law degree from a recognized university; plenty of legal knowledge about digital tokens, trading and smart contracts; the ability to create commercial agreements in line with local laws; and knowledge about how to take advantage of blockchain without running afoul of the law.

As more companies such as Marathon Digital Holdings Inc. (NASDAQ: MARA) are established, the number of high-paying jobs in the blockchain space will keep growing, and many more people will reap from the opportunities created by this industry.

Marathon Digital Holdings Inc. (MARA), closed Monday's trading session at $11.57, off by 6.8438%, on 16,546,758 volume. The average volume for the last 3 months is 16.375M and the stock's 52-week low/high is $5.20/$83.45.

Alliance Resource Partners L.P (ARLP)

The Online Investor, Zacks, TradersPro, MarketBeat, The Street, Marketbeat.com, MarketClub Analysis, InvestorPlace, TopStockAnalysts, QualityStocks, Dividend Opportunities, TheStockAdvisor, The Wealth Report, The Motley Fool, Money Morning, StreetAuthority Daily, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Daily Wealth, Daily Trade Alert, Rick Saddler, Wealth Insider Alert, The Growth Stock Wire, Trading Concepts, TheOptionSpecialist, TheStockAdvisors, SmarTrend Newsletters, TraderPower, Top Pros' Top Picks, Daily Markets, Trades Of The Day, Eagle Financial Publications, FNNO Newsletters, Greenbackers, Insider Wealth Alert, Short Term Wealth, Investor Update, Leeb's Market Forecast, TheTradingReport, TheStreet Offers, Money and Markets, PoliticsAndMyPortfolio.com, StreetInsider and Investment U reported earlier on Alliance Resource Partners L.P (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Coal is a nonrenewable fossil fuel that is used by most countries in the West as well as Asia to generate electricity. When burnt, this fuel produces carbon dioxide, which contributes greatly to global climate change by trapping heat in the earth’s atmosphere and in turn warming the planet.

Earlier this week, Greenpeace released a report confirming that China recently approved the construction of about 8.6GW of coal power in the first quarter of 2022, which represents almost one-half of the amount recorded last year. This approval comes as climate concerns increase amid rising global temperatures and dangerous weather events.

China had pledged to control power capacity from coal in the 2021–2025 period as it worked to reduce its carbon dioxide emissions by 2030. However, increasing worries about energy supply, which were partly caused by a series of power outages last year, have triggered more approvals.

In a research report, the environmental campaigning organization stated that the country’s provincial authorities had approved more coal power construction in an effort to sort out shortcomings in power generation. The environment group’s climate and energy campaigner, Wu Jinghan, who is based in Beijing, stated that energy security had become a code name for coal instead of referring to reliable energy supply. The National Energy Administration in China is yet to respond to a request for comment on the matter.

During the international climate talks held in Glasgow in 2021, the country’s plans to construct coal power plants were a point of contention, with most nations agreeing to gradually reduce their use of coal, instead of phasing it out completely. Currently, Beijing, which is the capital of China, is the biggest user and producer of coal. The city has pledged to begin reducing coal consumption after 2025. However, researchers with the State Grid have revealed that 150 gigawatts of new coal power capacity may have been constructed before then.

Additionally, recent forecasts from the country’s Electricity Council show that by 2025, the total power generation capacity of China is expected to have reached 3,000 gigawatts. Fossil fuel energy sources will make up almost 50% of this figure, which implies a 260 gigawatt increase in natural gas and coal-fired power, in comparison to the end of 2021.

Wu argued that even though China was accelerating solar and wind power construction, constructing more coal capacity would make it harder for renewable energy projects to access the power grids and reach consumers.

China isn’t the only country where there is a resurgence in the use of coal. Established coal miners such as Alliance Resource Partners L.P (NASDAQ: ARLP) are seeing the volumes of orders for coal rising with each passing month as the energy shortage deepens.

Alliance Resource Partners L.P (ARLP), closed Monday's trading session at $21.4, up 7.5918%, on 615,246 volume. The average volume for the last 3 months is 615,118 and the stock's 52-week low/high is $7.42/$21.66.

The QualityStocks Company Corner

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN) recently opened a newly renovated office in Metro Detroit (Troy, Michigan). The office is intended to enable the company to continue to forge close relationships with automakers centered around the heart of the U.S. auto industry. “Having a strong presence in Detroit not only enables us to keep up with the latest trend in the industry but also makes us part of that trend – we are here to demonstrate how lidar is essential to the future of mobility, with our product experts driving informative communications and our application engineers working in the field,” a recent article quotes Brunno Moretti, Cepton’s vice president of product and head of the Detroit office, as saying. The article reads: “As a provider of state-of-the-art lidar-based solutions with the mission to become one of the most prominent international players in the lidar space, Cepton has built what seems to be a truly global footprint. In addition to the San Jose, California, headquarters and the newly opened Troy operations, the company runs offices across the globe – from Germany and Canada to Japan, India, and China. The company appears to be successful in forging strong business ties with the auto industry’s key players. In addition to General Motors, the company also boasts an ongoing collaboration with Ford and engagements with the other top 10 automakers across the globe, as well as a five-year partnership with Koito, a leading automotive lighting tier-1 supplier.” To view the full article, visit https://ibn.fm/wuc0I

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $1.34, up 2.2901%, on 335,224 volume. The average volume for the last 3 months is 335,182 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion (NASDAQ: FNGR) is building a deeper channel for revenue in its services for China’s mobile phone users and big data clients. “FingerMotion’s central competencies are in mobile payment and mobile recharge platform solutions, but the company has been expanding into big data services through its Sapientus division. The data services have primarily been marketed as a tool for reinsurance companies as they look for effective measures of risk scoring and ways to simplify policy underwiring purchasing, but FingerMotion has acknowledged it could expand into other industries in the future,” a recent article reads. FingerMotion CEO Martin Shen is quoted saying, “We’ve always thought of the ability of the algorithms that we have. It’s not really just to perfect those algorithms but it’s also to have them exportable and replicated in other jurisdictions, in other markets… But again, that takes time to develop…. Right now, let’s just build and make sure that our foundation is strong first.” To view the full article, visit https://ibn.fm/z9jeX

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Monday's trading session at $1.32, up 6.0241%, on 17,653 volume. The average volume for the last 3 months is 17,653 and the stock's 52-week low/high is $1.08/$9.25.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”). Based on safety data of the first five adult patients who completed the phase 2 study, an independent data monitoring committee agreed it is safe to allow the enrollment of adolescent patients, defined as persons aged twelve to seventeen with EB. “We are pleased that the initial safety data from InMed’s phase 2 EB clinical trial has allowed the inclusion of adolescent patients,” said Alexandra Mancini, senior vice president of clinical and regulatory affairs at InMed. “With the inclusion of adolescents and increased number of patients available for screening, the target remains to complete enrollment of 20 patients in 2022.” To view the full press release, visit https://ibn.fm/C6qBh

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Monday's trading session at $0.4, up 4.9869%, on 167,636 volume. The average volume for the last 3 months is 167,636 and the stock's 52-week low/high is $0.3422/$2.95.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today urged shareholders to vote in favor of the proposals outlined in its definitive proxy statement for the upcoming annual shareholder meeting to be held Wednesday, July 27, 2022. Proposals include the authorization to increase the number of shares available for issuance by the company and the authorization for the board of directors to effect a reverse stock split of the outstanding shares of the company’s common stock, at a split ratio of between 1-for-2 and 1-for-30 at their discretion. To view the full press release, visit https://ibn.fm/pvMZV

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.23, up 2.4499%, on 193,935 volume. The average volume for the last 3 months is 192,315 and the stock's 52-week low/high is $0.22/$1.7958.

Recent News

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F)

The QualityStocks Daily Newsletter would like to spotlight Hillcrest Energy Technologies Ltd. (OTCQB: HLRTF).

  • Hillcrest announces AGM results; all seven members of Board of Directors are re-elected while new board chair David Farrell is appointed
  • Company exits fossil-fuel business and completes transition to clean tech market where it continues to develop inverter technology empowering next generation of more efficient and powerful electric vehicles
  • Hillcrest reaches key milestone as it completes proof of concept testing of its inverter technology, with the commercial prototype soon to be available in Q4 2022

Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA), a Canadian cleantech company developing technologies for innovative electrical solutions such as powertrains and grid-connected renewable energy systems, has announced the voting results from its Annual General Meeting held Wednesday, June 29, 2022. The Board of Directors and Management received extraordinary support from shareholders, who overwhelmingly voted in favor of the proposed items, including the composition of the Company's leadership. Hillcrest also announced the completion of its transition toward clean energy technologies by formally announcing the end of its oilfield activities (https://ibn.fm/pRIUD). Hillcrest (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA), a Vancouver, British Columbia-based company, is engaged in developing high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems. “Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (“EVs”), motors and generators. The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements,” a recent article reads. “Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high-efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry… Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure… Hillcrest sees this as a true EV charging game changer. The company’s technology applies to nearly every clean energy industry segment: wind and solar power, energy storage and EV fast chargers.” To view the full article, visit https://ibn.fm/ZDu5K

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) is a clean technology company based in Vancouver, British Columbia, engaged in developing high-value, high-performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable energy systems.

From concept to commercialization, Hillcrest invests in the development of energy solutions that power a more sustainable and electrified future. Hillcrest power inverter technology helps produce efficiencies in electrification and maximize the performance of electric systems, including electric vehicles (EV), motors and generators.

The company offers a flexible, single-inverter architecture that can be applied at nearly every stage of the electrification ecosystem, from renewable energy generation through the charging and operation of an EV, to provide full-cycle efficiency and performance improvements.

As momentum to electrify and decarbonize energy systems accelerates, Hillcrest believes the power inverter is increasingly emerging as a key component. While system cohorts such as battery packs, PV panels and electric motors are often in the spotlight, the inverter holds the key to unlocking efficiency and performance improvements.

Hillcrest power inverter technology is:

  • REVOLUTIONARY: high-efficiency inverter technology has the potential to revolutionize how motors respond and how efficiency is gained.
  • AGILE: able to deliver and deploy high-efficiency inverter solutions purpose-designed to meet specific customer needs.
  • INNOVATIVE: technology-forward, clean-energy experts who are focused on advancing and optimizing efficient alternative energy use across all electric vehicle and charging platforms.
  • A MARKET LEADER: a next-generation technology provider to the automotive industry’s top suppliers and manufacturers.

Technology & Applications

Hillcrest’s first application for its inverter technology – a 250 kW|800V Hillcrest SiC high efficiency traction inverter – is focused on the growing EV market. Hillcrest technology eliminates traditional design trade-offs faced across the power industry – deploying higher switching frequencies has historically meant a greater increase in losses, lower system efficiency and higher heat. Through a combination of hardware and software expertise, Hillcrest enables power applications to leverage higher switching frequencies AND

  • Realize improved power system performance and reliability
  • Operate at higher power levels without compromising efficiency

The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper, published in April 2022, that confirmed the following results:

  • Significant efficiency gains – 99%-plus inverter efficiency
  • Increased power density targeting 50kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts, enhancing reliability
  • Improved thermal management

Hillcrest has also filed a patent for an enhanced powertrain solution that offers the potential to simplify EV charging and redefine how the industry envisions charging infrastructure. The company believes the most exciting benefit of the enhanced powertrain solution is the ability to eliminate the onboard charger and booster from an EV, as well as faster, anywhere charging including direct DC, wireless, and bidirectional charging across current and future power levels. Hillcrest sees this as a true EV charging game changer.

The company’s technology applies to nearly every clean energy industry segment:

  • Wind power – an inverter is deployed at a wind turbine generator to convert the AC output, with at least one additional inverter used to deliver the power to the grid/battery.
  • Solar power – an inverter is used to convert the DC output from the photovoltaic panels into the AC power that flows to the grid/battery/home.
  • Energy storage – an inverter is deployed to convert the DC output from the storage system or batteries to the AC power that flows to the grid/home/EV.
  • EV fast chargers – an inverter converts the AC input from the grid/storage system to the DC output needed to charge an EV’s battery.

Market Outlook

According to an April 2022 market analysis by Vantage Market Research (VMR), the global power inverter market is expected to reach a value of $95 billion by 2028, driven by increasing demand for EVs, energy generating wind turbines and solar-powered photovoltaic systems. That jump is forecast from an estimated $70.5 billion market value in 2021 and represents a compound annual growth rate of more than 5%.

According to the VMR report, many governments in countries around the world are supporting alternative options for efficient and nonpolluting energy generation. This has boosted demand for wind energy and solar energy systems. Hillcrest is aiming to capture a share of this future market growth across nearly every segment of the clean energy industry.

Management Team

Don Currie is the founding CEO of Hillcrest Energy Technologies. He has led the company’s successful transition from fossil fuels into clean energy technologies. Earlier in his career, he held various senior level positions, including director, officer and vice president of corporate communications with Enhanced Oil Resources Inc., an oil and gas exploration and production company based in Houston. Prior to that, he worked in other private and public ventures spanning the mining, gaming and technology sectors.

Jamie L. Hogue is the COO of Hillcrest. She brings more than two decades of progressive policy leadership, economic analysis and organizational development experience to Hillcrest. She builds collaborative processes and solutions that drive growing organizations toward a more resilient future. She previously served as the director of operations for Arizona State University’s Ten Across initiative – a compelling observatory positioned on the front lines of economic, social and climate change. She earned a master’s degree in public administration and a bachelor’s degree in economics from Arizona State University.

Ari Berger is Chief Technology Officer at Hillcrest. He brings over a decade of commercial experience with a track record of deploying new electrification technologies and go-to-market strategies. In 2015, he founded NIG Systems Ltd. in Israel, which specializes in custom high performance control systems design. Prior to this, he previously worked for Bental Industries, a leading motor manufacturer. He holds a master’s degree in system control engineering from the Technion – Israel Institute of Technology.

Raj Clair is CFO at Hillcrest. She is a CPA who began her career at Deloitte and has served in advanced finance positions in the energy and resources sector. She has been responsible for reporting, audits and internal controls, as well as working on budgeting and forecasting. She has worked with various publicly listed companies, including SEC registrants, and has both Canadian and U.S. experience. She holds a bachelor’s degree in accounting from Simon Fraser University.

Hillcrest Energy Technologies Ltd. (NASDAQ: HLRTF), closed Monday's trading session at $0.103, up 10.6337%, on 19,020 volume. The average volume for the last 3 months is 19,020 and the stock's 52-week low/high is $0.075/$0.1826.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL), a mobile technology and marketing company, today announced its “Song of the Summer” contest and artist promotion. According to the update, the submission process opened to artists last week as the company received an immediate positive response with entries pouring in. The contest registration will remain open until July 31, 2022, and fan voting will begin in August 2022 to determine each of the five winners per genre. “This contest has been a highly sought after and anticipated promotion since it began with the former Artist Republik management team,” said Friendable CEO Robert A. Rositano Jr. “Now that our team has taken over, it’s our pleasure to have revamped the contest with new technology, tracking, leader boards, promotion, and tools for each artist to promote themselves to fans to attract the most votes to their ‘Song of the Summer’ submission. In previous years, the promotion has garnered over 10,000 sign-ups, but the artists have never had the opportunity to engage with their fans beyond the vote. With our 360 offering, including Artist Republik services, FeaturedX and Fan Pass Live, each artist can continue monetizing from the fan engagement created by our promotion, further gathering more content, traffic and revenue for the company overall.” To view the full press release, visit https://ibn.fm/gDtoL

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Monday's trading session at $0.0003, up 50%, on 174,219,482 volume. The average volume for the last 3 months is 174.219M and the stock's 52-week low/high is $0.00015/$0.018.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

  • Nearly a decade has passed since approximately 200 government entities met in Paris, ratifying a binding agreement to work toward reducing pollution and its negative impacts on global climate
  • Louisiana-based Correlate Infrastructure Partners is helping to educate corporate clients on both the affordability and potential profit offered by ESG solutions that reduce their greenhouse gas impact
  • CIPI’s Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design) subsidiaries provide related help on acquisitions and project development, as well as resource financing 
  • A recent report by consulting firm McKinsey & Company forecasts growing adoption of renewable energy solutions by the public, but at a pace that will, at the current rate, fall short of the established Paris goals

Purpose-built energy use optimization company Correlate Infrastructure Partners (OTCQB: CIPI) works with business clients to improve their facilities’ consumption of utilities and production of greenhouse gases. Environmental, social and governance (“ESG”) initiatives have become increasingly important amid concerns about climate change and its expected negative effects on society. Correlate Infrastructure Partners (OTCQB: CIPI), a technology-enabled energy optimization and clean-energy solutions provider for North America, has entered into a nonbinding letter of intent (“LOI”) outlining its plans to acquire a top-10 solar, battery storage and roofing provider based in California. According to the announcement, the target company focuses on sales and self-performance construction of solar and roofing services for residential and commercial properties; CIPI anticipates the acquisition to be complete and accretive by the second half of this year, marking the “next evolution” of the company as a community-scale distributed energy company. Highlights of the agreement include expanded national leadership in key markets; expertise in regional permitting and interconnection for key residential and commercial solar-plus storage markets; integrated digital technologies; and a loyal user base of sales partners and end customers; cost efficiencies that improve market position. Once the acquisition is complete, the company also anticipates the aggregation of tens of thousands of residential and commercial customer sites and electric vehicles into distributed, virtual power plants (“VPPs”) that can provide grid services and community-scale resilience. “While Correlate continues to innovate its core platform services for commercial properties, we are actively integrating complementary energy service providers that align with our mission and strengthen our regional execution prowess,” said Correlate Infrastructure Partners CEO and president Todd Michaels in the press release. “We intend to create one of the first profitable and truly scalable distributed energy platforms in all of North America that ensures an optimum customer experience long term.” To view the full press release, visit https://ibn.fm/CXaLv

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Monday's trading session at $1.25, even for the day, on 4,900 volume. The average volume for the last 3 months is 4,900 and the stock's 52-week low/high is $0.3021/$3.25.

Recent News

DPCM Capital Inc. (NYSE: XPOA)

The QualityStocks Daily Newsletter would like to spotlight DPCM Capital Inc. (NYSE: XPOA).

DPCM Capital (NYSE: XPOA) recently entered into a definitive transaction agreement with D-Wave Systems Inc., whereby, upon closing of the transaction, shares of the pending parent company – D-Wave Quantum Inc. – are expected to trade on the NYSE under ticker symbol QBTS. D-Wave Systems, a leader in quantum computing systems, software and services, and the only company building both quantum annealing and gate-based quantum computers, and Mastercard (NYSE: MA) recently announced a multi-year strategic alliance to champion the acceleration and adoption of quantum computing solutions. According to the announcement, D-Wave and Mastercard will collaborate on the research and development of quantum-hybrid applications in areas such as consumer loyalty and rewards, cross-border settlement and fraud management. To view the full press release, visit https://ibn.fm/YVC07

DPCM Capital Inc. (NYSE: XPOA), a special purpose acquisition company, on February 9, 2022, announced its entry into a definitive transaction agreement with D-Wave Systems Inc., a company with approximately 20 years of experience in pioneering superconducting annealing quantum computers. Upon closing of the transaction, shares of D-Wave Quantum Inc. – a newly formed company that will be the parent company of D-Wave Systems and DPCM Capital – are expected to trade on the NYSE under ticker symbol ‘QBTS’.

The transaction, which is subject to the satisfaction of customary closing conditions, is expected to enhance D-Wave’s leadership in commercial quantum computing and accelerate quantum use cases into significant customer segments.

D-Wave is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

DPCM Capital Inc. (NYSE: XPOA), closed Monday's trading session at $9.98, off by 0.2%, on 596,674 volume. The average volume for the last 3 months is 596,674 and the stock's 52-week low/high is $9.65/$10.33.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patents
  • Recently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan
  • The patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent family
  • Lexaria also submitted a briefing book to the FDA to facilitate its upcoming pre-Investigational New Drug (“IND”) meeting with the agency

“We are extremely pleased to have received our first patent protecting our proprietary technology… I expect our intellectual property portfolio to continue to expand,” said Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka in an October 2016 press release announcing that the company had been issued U.S. Patent No. 9,474,725, Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof, by the U.S. Patent and Trademark Office (“USPTO”) (https://cnw.fm/AxzvE).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $2.705, off by 3.3929%, on 65,374 volume. The average volume for the last 3 months is 65,374 and the stock's 52-week low/high is $1.85/$8.4799.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

The marijuana industry has grown significantly these last few years. A good way to determine just how rapidly it has grown is to look at how many employment opportunities the industry has created thus far. A new report by Leafly reported that roughly 280 new marijuana jobs are created every day. Cumulatively, this added up to an estimated 428,000 jobs by January 2022, making this particular industry one of the fastest-growing employers in the United States. This growth is particularly impressive if someone considers that it has been less than a decade since the states of Washington and Colorado began legal weed sales. It also makes the marijuana industry and other related industries, such as legal work and marketing, good places to look for jobs. As the jobs report shows, industry players such as Flora Growth Corp. (NASDAQ: FLGC) are contributing the community development by, among other things, availing high-paying jobs to residents.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Monday's trading session at $0.65, off by 1.5152%, on 270,561 volume. The average volume for the last 3 months is 268,671 and the stock's 52-week low/high is $0.61/$21.45.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

  • Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months
  • The pivotal study was designed with four primary objectives
  • Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD

Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. With speculation about psychedelics at an all-time high and the market projected to grow exponentially in the next few years, psychedelic stocks have been a draw for many investors. However, given that the market is still new and has plenty of legal and regulatory challenges to surpass, investors interested in psychedelic stocks should exercise caution when investing their hard-earned cash. Most psychedelic companies are young with no record of success; many still have to go through long and costly clinical trials as well. This means that many of these fledgling companies are relying on debt to finance research and development. This makes psychedelic stocks an risky venture for even the most experienced investors. However, by following the right approach, including the tips outlined below, investors may experience decent returns on your psychedelic stocks. When you follow the suggestions above, you are more likely to make an accurate assessment of the potential of stocks offered by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN).

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Monday's trading session at $0.56, off by 0.691612%, on 627,525 volume. The average volume for the last 3 months is 616,579 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

  • Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories
  • Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery
  • SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis
  • Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”) (https://ibn.fm/BizI3). The police don’t have a good reputation when it comes to dealing with individuals with mental health crises. Police encounters have repeatedly proven to be particularly dangerous for people with mental illness, with these encounters often ending in injury and failing to provide the involved individuals the mental help they need. Even so, a recent study has revealed that university health centers in the Ontario region still rely on law enforcement for emergency mental-health transfers. The study, whose findings were reported in the “Canadian Medical Association Journal,” shows that health practitioners often prefer to call the police, even though they regularly use physical restraints and their altercations often end in injury. With suicidal behavior and self-harm rates among Canadian university students on the rise, investigators led by Juveria Zaheer, University of Toronto assistant professor of psychiatry, sought to investigate how physicians in Ontario-area universities responded to students in mental distress. What would be of great help is a new generation of medications for mental health illnesses? Companies such as Silo Pharma Inc. (OTCQB: SILO) are on the hunt for novel treatments that can address mental health issues in a way that offers lasting results and supports patients, hopefully decreasing emergency mental health situations.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Monday's trading session at $0.134, off by 4.2857%, on 112,075 volume. The average volume for the last 3 months is 112,075 and the stock's 52-week low/high is $0.0892/$0.2489.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.